Fantastic collaboration with world-class radiologists at The Alfred , bringing more trials to patients. Prof. Warren Clements #worldcancerday2021

It's Monday AM post-ASCO #GU21 & clinic starts in a couple of hours! Lots to process - I'll try to tackle optimal 1L tx for #kidneycancer. I'll make a case for cabo/nivo, leaning on the beautiful (& timely) tables below from Aly-Khan Lalani, Andrey Soares & Brian Rini, MD (1/15)

Dr. Mark Voskobynik mark voskoboynik will be presenting a Trials In Progress poster at #AACR21 on ALPN-202, our first-in-class conditional CD28 costimulator/dual PD-L1/CTLA-4 inhibitor. Learn more about the NEON-1 trial for patients with #cancer. More details: ir.alpineimmunesciences.com/news-releases/…

Congrats to mark voskoboynik & team The Alfred for randomising 1st 2 pts on #UpFrontPSMA! A first-in-field study of #LuPSMA in mHS #ProstateCancer. Thx to funders (Movember Australia , MRFF, DoD) and especially patients & families. clinicaltrials.gov/ct2/show/NCT04…

Cancer patients in Gippsland will have better access to clinical trials locally thanks to a partnership between Alfred Health’s Trialhub and Latrobe Regional Hospital. More: bit.ly/3tEirga

LATE PHASE 1 STUDY. A new highly needed design. thelancet.com/journals/lanon… Gustave Roussy Jose Carlos Benitez arthur geraud Christophe Massard soria

Just out in Annals of Oncology, results of the first-in-human phase 1 study of the anti–TIGIT antibody vibostolimab as monotherapy or in combination with pembrolizumab. The patient population included anti–PD-1/PD-L1‒refractory NSCLC 🫁 annalsofoncology.org/article/S0923-…

It is this time of the year again: TOP 20 GU Oncology clinical trials published in 2021: Some negative, some positive, some led to FDA Oncology approval; we learned from all! Feel free to add & retweet & tag anyone involved This is not an exhaustive list OncoAlert

🥁Thrilled to announce that our paper is out Nature Medicine! We looked at the impact of nivolumab/ipilimumab +/- #CBM588 a bifidogenic live bacterial product, on gut #Microbiome, serum cytokines & clinical outcomes in #mRCC 🙏🙏Sumanta K. Pal, MD, FASCO Luis A. Meza Paulo G Bergerot et al. 1/n🧵

162/162 randomised on the ENZAp trial. Primary endpoint PSA-PFS enzalutamide vs enzalutamide + Lu PSMA-617. Huge translational side. Matched serial PSMA (FDG) PET, SPECT, RECIST, CTC, ctDNA - prognostic, predictive and interim response biomarkers. Thx everyone involved!

So exciting to see this new work published on immunotherapy impacts to fertility Nature Cancer. This research strongly advocates we must include reproductive endpoints in clinical trials moving forward! nature.com/articles/s4301…

Feeling young after being able to snap 📸 a #Wefie with graduates of ESMO - Eur. Oncology Asia #LGP programme. Thanks mentors including Ravindran Kanesvaran for mentoring a new generation of oncology leaders in our region! Annie Wong 黃毅敏 Eileen Poon Rachel Wong #mentorship #ESMOAsia22

Highlighting the need for better #diversity in #ClinicalTrials and the need to provide these services where people actually live. EHCS Monash Eastern Health Monash Medicine, Nursing and Health Sciences ACTA: Australian Clinical Trials Alliance Herald Sun

The ESMO - Eur. Oncology leadership course is one of the best things I’ve done 🌏 Focussing on oncology issues for Asia-Pacific region 👥 Comms/leadership skills 🤩 Connecting with new colleagues/friends/ESMO mentors Apply now 👇

ENZA-P in The Lancet Oncology Lu-177 PSMA-617 + enzalutamide vs. enza alone: ● ↑PFS: 13.0 vs 7.8, hazard radio 0.43 ● PSA90 response 78% vs 37% ● PSA50 response 93% vs. 68% ● no additional side effects Incredible work from Louise Emmett Ian Davis & ANZUP team

ENZA-p trial The Lancet Oncology authors.elsevier.com/a/1iw3e5EIIgPd… Enzalutamide + adaptive-dosed (2 or 4) 177 Lu-PSMA617 vs enza alone in mCRPC. Biomarker guided combination therapy works! Better response depth/duration with no added tox. ANZUP NHMRC CTC Movember Australia @SVHSydney

(1/3) ALPN-202 (davo) is a novel agent that inhibited PD-1/CTLA-4 with PD-L1-dependent CD28 co-stim. Dose-escalated singly (NEON-1) & with pembro (NEON-2). Dose-dependent PK both as mono and combo with moderate ADA incidence (14% vs. 24%). jitc.bmj.com/content/12/8/e…

Davoceticept as monotherapy and in combination with pembrolizumab in advanced solid tumors Journal for ImmunoTherapy of Cancer Diwakar Davar, M.D. Ludimila Cavalcante mark voskoboynik Rachel E. Sanborn, MD Justin Gainor #Cancer #OncoDaily #Oncology #CancerCare #CancerResearch oncodaily.com/119169.html

☢ UpFrontPSMA "Live #ESMO24": Lutetium-177 PSMA-617 followed by docetaxel improved anti-tumour activity in men with new diagnosis of metastatic hormone-sensitive prostate cancer compared with docetaxel alone, without increased side effects 🔥Hot off the press The Lancet Oncology:

When you firebomb a synagogue with people inside & attack a local restaurant because it’s owned by Jews, it’s NOT about Israel, it’s NOT about protest, it’s a hate crime. Violent antisemitism is a threat to us all & until it’s called out for what it really is, it will continue!